Cyteir Therapeutics Was A Clinical Stage Biotechnology Company Located In Massachusettsfocused On Developing Innovative Therapies For Cancer And Autoimmune Diseasesthe Company Specialized In Next Generation Synthetically Lethal Therapiesparticularly Targeting Hematological Cancers And Solid Tumorsone Of Their Key Products Was Cyt 0851An Oral Investigational Drug Candidate Designed To Inhibit Monocarboxylate Transportersmcts This Drug Was Evaluated In Clinical Studies Both As A Monotherapy And In Combination With Standard Care Therapies For Treating Patients With Hematologic Malignancies And Solid Tumorsadditionallycyt 0851 Was Being Tested In Combination With Capecitabine And Gemcitabine For Advanced Ovarian Cancer As Of 2024Cyteir Therapeutics Has Ceased Operationsat Its Peakthe Company Employed Around 46 People
